Translational failure of anti-inflammatory compounds for myocardial infarction: A meta-Analysis of large animal models

Cardiovascular Research

Volumn 109, Issue 2, 2016, Pages 240-248

  Van Hout, Gerardus P J ^a   Jansen Of Lorkeers, Sanne J ^a   Wever, Kimberly E ^b   Sena, Emily S ^c   Kouwenberg, Lisanne H J A ^a   Van Solinge, Wouter W ^a   Macleod, Malcolm R ^c   Doevendans, Pieter A ^a   Pasterkamp, Gerard ^a   Chamuleau, Steven A J ^a   Hoefer, Imo E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Anti inflammatory; Infarct size reduction; Large animal model; Myocardial infarction; Translational failure

Indexed keywords

ANTIINFLAMMATORY AGENT;

ARTICLE; DRUG EFFICACY; DRUG TREATMENT FAILURE; EFFECT SIZE; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; ANIMAL; DISEASE MODEL; DRUG EFFECTS; HEART VENTRICLE; MEDLINE; META ANALYSIS; MYOCARDIAL INFARCTION; PROCEDURES; TRANSLATIONAL RESEARCH;

ANIMALS; ANTI-INFLAMMATORY AGENTS; DISEASE MODELS, ANIMAL; HEART VENTRICLES; MYOCARDIAL INFARCTION; PUBMED; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84959906037     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvv239     Document Type: Article

References (58)

1. Gupta A, Wang Y, Spertus JA, Geda M, Lorenze N, Nkonde-Price C, DOnofrio G, Lichtman JH, Krumholz HM. Trends in acute myocardial infarction in young patients and differences by sex and race, 2001 to 2010. J Am Coll Cardiol 2014;64:337-345.
2. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB. Heart Disease and Stroke Statistics-2014 Update: A report from the American Heart Association. Circulation 2014;129: e28-e292.
3. Bleumink GS, Knetsch AM, Sturkenboom MCJM, Straus SMJM, Hofman A, Deckers JW, Witteman JCM, Stricker BHC. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure-The Rotterdam Study. Eur Heart J 2004;25:1614-1619.
4. Sutton MG, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy. Circulation 2000;101:2981-2988.
5. Timmers L, Pasterkamp G, de Hoog VC, Arslan F, Appelman Y, de Kleijn DP. The innate immune response in reperfused myocardium. Cardiovasc Res 2012;94:276-283.
6. Arslan F, de Kleijn DP, Pasterkamp G. Innate immune signaling in cardiac ischemia. Nat Rev Cardiol 2011;8:292-300.
7. Christia P, Frangogiannis NG. Targeting inflammatory pathways in myocardial infarction. Eur J Clin Invest 2013;43:986-995.
8. Timmers L, Sluijter JPG, Verlaan CWJ, Steendijk P, Cramer MJ, Emons M, Strijder C, Gründeman PF, Sze SK, Hua L, Piek JJ, Borst C, Pasterkamp G, de Kleijn DP. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007;115: 326-332.
9. Vinten-Johansen J. Involvement of neutrophils in the pathogenesis of lethal myocardial reperfusion injury. Cardiovasc Res 2004;61:481-497.
10. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res 2002;53:31-47.
11. Arslan F, Smeets MB, ONeill LA, Keogh B, McGuirk P, Timmers L, Tersteeg C, Hoefer IE, Doevendans PA, Pasterkamp G, de Kleijn DP. Myocardial ischemia/reperfusion injury is mediated by leukocytic toll-like receptor-2 and reduced by systemic administration of a novel anti-Toll-like receptor-2 antibody. Circulation 2010;121:80-90.
12. van der Laan AM, Hirsch A, Robbers LF, Nijveldt R, Lommerse I, Delewi R, van der Vleuten PA, Biemond BJ, Zwaginga JJ, van der Giessen WJ, Zijlstra F, van Rossum AC, Voermans C, van der Schoot CE, Piek JJ. A proinflammatory monocyte response is associated with myocardial injury and impaired functional outcome in patients with ST-segment elevation myocardial infarction: Monocytes and myocardial infarction. Am Heart J 2012;163:57-65.e2.
13. Núñez J, Núñez E, Bodí V, Sanchis J, Minãna G, Mainar L, Santas E, Merlos P, Rumiz E, Darmofal H, Heatta AM, Llàcer A. Usefulness of the neutrophil to lymphocyte ratio in predicting long-Term mortality in ST segment elevation myocardial infarction. Am J Cardiol 2008;101:747-752.
14. Blum A, Sclarovsky S, Rehavia E, Shohat B. Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interleukin-2 receptor in acute myocardial infarction. Am Heart J 1994;127:1226-1230.
15. Takahashi T, Hiasa Y, Ohara Y, Miyazaki S-I, Ogura R, Suzuki N, Hosokawa S, Kishi K, Ohtani R. Relationship of admission neutrophil count to microvascular injury, left ventricular dilation, and long-Term outcome in patients treated with primary angioplasty for acute myocardial infarction. Circ J 2008;72:867-872.
16. Maekawa Y, Anzai T, Yoshikawa T, Asakura Y, Takahashi T, Ishikawa S, Mitamura H, Ogawa S. Prognostic significance of peripheral monocytosis after reperfused acute myocardial infarction: A possible role for left ventricular remodeling. J Am Coll Cardiol 2002;39:241-246.
17. van der Laan AM, Nahrendorf M, Piek JJ. Healing and adverse remodelling after acute myocardial infarction: role of the cellular immune response. Heart 2012;98: 1384-1390.
18. Lecour S, Botker HE, Condorelli G, Davidson SM, Garcia-Dorado D, Engel FB, Ferdinandy P, Heusch G, Madonna R, Ovize M, Ruiz-Meana M, Schulz R, Sluijter JPG, van Laake LW, Yellon DM, Hausenloy DJ. ESCWorking Group Cellular Biology of the Heart: Position Paper: improving the preclinical assessment of novel cardioprotective therapies. Cardiovasc Res 2014;104:399-411.
19. Hausenloy DJ, Baxter G, Bell R, Bøtker HE, Davidson SM, Downey J, Heusch G, Kitakaze M, Lecour S, Mentzer R, Mocanu MM, Ovize M, Schulz R, Shannon R, Walker M, Walkinshaw G, Yellon DM. Translating novel strategies for cardioprotection: The Hatter Workshop Recommendations. Basic Res Cardiol 2010;105:677-686.
20. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, Xu W, Richards DR, McDonald-Smith GP, Gao H, Hennessy L, Finnerty CC, López CM, Honari S, Moore EE, Minei JP, Cuschieri J, Bankey PE, Johnson JL, Sperry J, Nathens AB, Billiar TR, West MA, Jeschke MG, Klein MB, Gamelli RL, Gibran NS, Brownstein BH, Miller-Graziano C, Calvano SE, Mason PH, Cobb JP, Rahme LG, Lowry SF, Maier RV, Moldawer LL, Herndon DN, DavisRW, XiaoW, Tompkins RG. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013; 110:3507-3512.
21. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G. Ischemic postconditioning in pigs: No causal role for risk activation. Circ Res 2009;104:15-18.
22. Timmers L, Henriques JP, de Kleijn DP, Devries JH, Kemperman H, Steendijk P, Verlaan CW, Kerver M, Piek JJ, Doevendans PA, Pasterkamp G, Hoefer IE. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009;53:501-510.
23. Houtgraaf JH, de Jong R, Kazemi K, de Groot D, van der Spoel TI, Arslan F, Hoefer I, Pasterkamp G, Itescu S, Zijlstra F, Geleijnse ML, SerruysPW, Duckers HJ. Intracoronary infusion of allogeneic mesenchymal precursor cells directly after experimental acute myocardial infarction reduces infarct size, abrogates adverse remodeling, and improves cardiac function. Circ Res 2013;113:153-166.
24. Arslan F, Houtgraaf JH, Keogh B, Kazemi K, de Jong R, McCormack WJ, ONeill LA, McGuirk P, Timmers L, Smeets MB, Akeroyd L, Reilly M, Pasterkamp G, de Kleijn DP. Treatment with OPN-305, a humanized anti-Toll-like receptor-2 antibody, reduces myocardial ischemia/reperfusion injury in pigs. Circ Cardiovasc Interv 2012;5: 279-287.
25. Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E. Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest 1973;52:599-607.
26. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
27. Seropian IM, Toldo S, van Tassell BW, Abbate A. Anti-inflammatory strategies for ventricular remodeling following St-segment elevation acute myocardial infarction. J Am Coll Cardiol 2014;63:1593-1603.
28. van der Worp HB, Macleod MR. Preclinical studies of human disease: Time to take methodological quality seriously. J Mol Cell Cardiol 2011;51:449-450.
29. Sena ES, Bart van derWorp H, Bath PMW, HowellsDW, Macleod MR. Publication bias in reports of animal stroke studies leads to major overstatement of efficacy. PLoS Biol 2010;8:e1000344.
30. van der Worp HB, Howells DW, Sena ES, Porritt MJ, Rewell S, OCollins V, Macleod MR. Can animal models of disease reliably inform human studies? PLoS Med 2010;7:e1000245.
31. Jansen of Lorkeers SJ, Eding JEC, Vesterinen HM, van der Spoel TI, Sena ES, Duckers HJ, Doevendans PA, Macleod MR, Chamuleau SAJ. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-Analysis of large animal studies. Circ Res 2014;116:80-86.
32. van Hout GPJ, Jansen of Lorkeers SJ, Wever KE, Sena ES, van Solinge WW, Doevendans PA, Pasterkamp G, Chamuleau SAJ, Hoefer IE. Anti-inflammatory compounds to reduce infarct size in large-Animal models of myocardial infarction: A meta-Analysis. Evidence based Preclin Med 2014;1:4-10.
33. Vesterinen HM, Sena ES, Egan KJ, Hirst TC, Churolov L, Currie GL, Antonic A, HowellsDW, Macleod MR. Meta-Analysis of data from animal studies: A practical guide. J Neurosci Methods 2014;221:92-102.
34. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-Analysis detected by a simple, graphical test. BMJ 1997;315:629-634.
35. Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-Analysis. Biometrics 2000;56:455-463.
36. Lugrin J, Parapanov R, Rosenblatt-Velin N, Rignault-Clerc S, Feihl F, Waeber B, Muller O, Vergely C, Zeller M, Tardivel A, Schneider P, Pacher P, Liaudet L, Müller O, Vergely C, Zeller M, Tardivel A, Schneider P, Pacher P, Liaudet L. Cutting edge: IL-1 is a crucial danger signal triggering acute myocardial inflammation during myocardial infarction. J Immunol 2014;194:499-503.
37. Frangogiannis NG. The inflammatory response in myocardial injury, repair, and remodelling. Nat Rev Cardiol 2014;11:255-265.
38. Mahaffey KW, Granger CB, Nicolau JC, Ruzyllo W, Weaver WD, Theroux P, Hochman JS, Filloon TG, Mojcik CF, Todaro TG, ArmstrongPW. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003;108:1176-1183.
39. Armstrong PW, Granger CB, Adams PX, Hamm C, Holmes D, ONeill WW, Todaro TG, Vahanian A, van deWerf F. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. JAMA 2007;297:43-51.
40. BaranKW, Nguyen M, McKendall GR, Lambrew CT, DykstraG, Palmeri ST, Gibbons RJ, Borzak S, Sobel BE, Gourlay SG, Rundle AC, Gibson CM, Barron HV. Double-blind, randomized trial of an anti-CD18 antibody in conjunction with recombinant tissue plasminogen activator for acute myocardial infarction: limitation of myocardial infarction following thrombolysis in acute myocardial infarction (LIMIT AMI) stu. Circulation 2001;104:2778-2783.
41. Faxon DP, Gibbons RJ, Chronos NA, Gurbel PA, Sheehan F. The effect of blockade of the CD11/CD18 integrin receptor on infarct size in patients with acute myocardial infarction treated with direct angioplasty: The results of the HALT-MI study. J Am Coll Cardiol 2002;40:1199-1204.
42. MacLeod MR, van der Worp HB, Sena ES, Howells DW, Dirnagl U, Donnan GA. Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke 2008;39:2824-2829.
43. Jansen Of Lorkeers SJ, Doevendans PA, Chamuleau SA. All preclinical trials should be registered in advance in an online registry. Eur J Clin Invest 2014;44:891-892.
44. Macleod MR, Fisher M, OCollins V, Sena ES, Dirnagl U, Bath PMW, Buchan A, van der Worp HB, Traystman R, Minematsu K, Donnan GA, Howells DW. Good laboratory practice: preventing introduction of bias at the bench. Stroke 2008;40:e50-e52.
45. Platt ML, Hayden B. Learning: Not Just the Facts, Ma am, but the Counterfactuals as Well. PLoS Biol 2011;9:1-2.
46. Vander Heide RS, Steenbergen C. Cardioprotection and myocardial reperfusion: pitfalls to clinical application. Circ Res 2013;113:464-477.
47. Lukács E, Magyari B, Tó th L, Petrási Z, Repa I, Koller A, Horváth I. Overview of large animal myocardial infarction models (review). Acta Physiol Hung 2012;99:365-381.
48. Verdouw PD, van den Doel MA, de Zeeuw S, Duncker DJ. Animal models in the study of myocardial ischaemia and ischaemic syndromes. Cardiovasc Res 1998;39:121-135.
49. Mather AN, Fairbairn TA, Artis NJ, Greenwood JP, Plein S. Timing of cardiovascular MR imaging after acute myocardial infarction: effect on estimates of infarct characteristics and prediction of late ventricular remodeling. Radiology 2011;261:116-126.
50. Ma N, Szabolcs MJ, Sun J, Albala A, Sciacca RR, Zhong M, Edwards N, Cannon PJ. The effect of selective inhibition of cyclooxygenase (COX)-2 on acute cardiac allograft rejection. Transplantation 2002;74:1528-1534.
51. Sunamori M. Protective effect of betamethasone on the subendocardial ischemia after the cardiopulmonary bypass. J Cardiovasc Surg (Torino) 1978;19:291-310.
52. Feola M, Rovetto M, Soriano R, Cho SY, Wiener L. Glucocorticoid protection of the myocardial cell membrane and the reduction of edema in experimental acute myocardial ischemia. J Thorac Cardiovasc Surg 1976;72:631-643.
53. Sprague RS, Stephenson AH, Dahms TE, Lonigro AJ. Proposed role for leukotrienes in the pathophysiology of multiple systems organ failure. Crit Care Clin 1989;5:315-329.
54. Dong M, Mu N, Ren F, Sun X, Li F, Zhang C, Yang J. Prospective study of effects of endogenous estrogens on myocardial no-reflow risk in postmenopausal women with acute myocardial infarction. J Interv Cardiol 2014;27:437-443.
55. Zhou C, Yao Y, Zheng Z, Gong J, WangW, Hu S, Li L. Stenting technique, gender, and age are associated with cardioprotection by ischaemic postconditioning in primary coronary intervention: A systematic review of 10 randomized trials. Eur Heart J 2012;33: 3070-3077.
56. Lawesson SS, Alfredsson J, Fredrikson M, Swahn E. Time trends in STEMI-improved treatment and outcome but still a gender gap: A prospective observational cohort study from the SWEDEHEART register. BMJ Open 2012;2:e000726.
57. Lagranha CJ, Deschamps A, Aponte A, Steenbergen C, Murphy E. Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res 2010;106:1681-1691.
58. Knowlton AA, Lee AR. Estrogen and the cardiovascular system. Pharmacol Ther 2012; 135:54-70.